GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis
NCT07617155 on ClinicalTrials.gov · last registry update 2026-06-01
An unusually large phase 4: 396 participants, more than double the 72 typical for the stage. Due to report September 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Proportion of participants with recurrent hypertriglyceridemia-induced acute pancreatitis. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- NOT_YET_RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Peking Union Medical College Hospital
- Sponsor type
- Other
- Enrollment
- 396
- Started
- 2026-09
- Primary completion
- 2028-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Proportion of participants with recurrent hypertriglyceridemia-induced acute pancreatitis
Conditions studied
Hypertriglyceridemia Induced Acute Pancreatitis · Recurrent Acute Pancreatitis · Pancreatitis Relapsing · Hypertriglyceridemia
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.